Abstract:BACKGROUND: In the United States, the shift towards value-based health care seeks to improve patient outcomes while reducing health care spending. Although the federal government has led the implementation of performance-based models for physicians and health care systems, commercial entities have largely been responsible for the development of similar models within pharmacy. For the purposes of this study, performance-based pharmacy payment models (PBPPMs) were defined as prescription drug payment models that determine reimbursement or fees for community pharmacies based in part on measured performance. These PBPPMs incentivize pharmacies to improve patient care by linking reimbursement to performance measures. However, the design and implementation of PBPPMs lack transparency and have not been described in the literature. OBJECTIVES: To (1) describe the structure of PBPPMs in the United States and (2) identify contextual and motivational influences that need to be considered for successful uptake and integration of these models. METHODS: A search of peer-reviewed and grey literature was undertaken. In addition, semi-structured stakeholder interviews were conducted with a convenience sample of 17 individuals who were community pharmacists, payers, quality measure developers and vendors, academics, and pharmacy advocacy organization leaders. Data were analyzed to understand the current structure of PBPPMs and opportunities for improvement, as well as implementation considerations that included facilitators, barriers, and key insights. RESULTS: This study identified 4 major components of US PBPPMs: attribution, performance and quality measures, incentive structures, and patient care services. A number of barriers (eg, lack of alignment) and recommendations to improve the current structure of PBPPMs (eg, the need for adequate incentives to facilitate change) were highlighted. Notable implementation considerations centered around (1) establishing common ground among stakeholders to avoid misalignment and encourage engagement; (2) the importance of a quality-driven, innovative, and flexible organizational culture with access to data infrastructure, adjusted workflows, and relevant trainings; (3) supporting the cultural transition to value-based health care; and (4) application of financial incentives at the pharmacy or pharmacist level. CONCLUSIONS: To better develop and implement PBPPMs, it is first critical to understand the key components that define these models and the needed changes to their structure. In addition, identifying the contextual and motivational factors that influence their successful integration can improve future uptake. This study illustrates the landscape of PBPPMs in the United States, as well as makes recommendations for improvement in their design. To improve future development and implementation of these models, the following recommendations are highlighted: (1) increase transparency and alignment of measures with the incentive structure; (2) embrace innovative business models; (3) carefully plan and use roadmaps that outline successful uptake and implementation; and (4) foster culture of quality at all levels of health care. DISCLOSURES: This study was sponsored by Pharm-Alliance, an alliance between the pharmacy schools of the University of North Carolina at Chapel Hill, Monash University, and University College London. Urick reports consulting fees from Pharmacy Quality Solutions and Cardinal Health, unrelated to this work. The other authors have nothing to disclose. This study was a podium presentation under the title "What Makes Performance-Based Pharmacy Payment Models Work?" at AMCP Nexus Virtual, October 2020.

Adoption of value-based pricing for prescription drugs

Operationalizing value-based pricing of medicines : a taxonomy of approaches

Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration

Unraveling elements of value-based pricing from a pharmaceutical industry's perspective: a scoping review

International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature

Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required

Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries

Implementation and Utilization of Real-time Prescription Benefit Tools Across Three Large Academic Health Systems

Experiences and Interest in Value‐Based Payment Arrangements for Medical Products Among Medicaid Agencies: An Exploratory Analysis

Application of the Price–Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy

Multiple criteria qualitative value-based pricing framework "MARIE" for new drugs

Payer perceptions and use of value assessment tools in the United States

Question-based drug development and the value of novel treatments

Consumers' Perceptions And Choices Related To Three Value-Based Insurance Design Approaches

Pricing Personalised Drugs: Comparing Indication Value Based Prices with Performance Based Schemes

Feasibility and attractiveness of indication value-based pricing in key EU countries

Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program

Precision reimbursement for precision medicine: the need for patient-level decisions between payers, providers and pharmaceutical companies

Escalating costs of innovative medicines: perspective and proposals

When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs

Assessment of the utilization of real-time prescription benefits for patient cost savings within an outpatient setting